Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.02 EUR
Change Today -0.10 / -1.95%
Volume 44.2K
As of 9:54 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

mauna kea technologies (MKEA) Snapshot

Open
€5.12
Previous Close
€5.12
Day High
€5.19
Day Low
€5.01
52 Week High
04/1/14 - €13.27
52 Week Low
10/16/14 - €4.68
Market Cap
70.9M
Average Volume 10 Days
45.3K
EPS TTM
--
Shares Outstanding
14.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MAUNA KEA TECHNOLOGIES (MKEA)

Related News

No related news articles were found.

mauna kea technologies (MKEA) Related Businessweek News

No Related Businessweek News Found

mauna kea technologies (MKEA) Details

Mauna Kea Technologies S.A. engages in the design, development, and manufacture of medical devices for medical imaging. The company offers Cellvizio, a probe-based Confocal Laser Endomicroscopy solution that performs microscopic imaging. Its Cellvizio platform provides various Confocal Miniprobes to answer the specific needs of each endoscopy field comprising GastroFlex for Eso-Gastro-Duodenoscopy; CholangioFlex for Confocal Cholangioscopy in ERCP; ColoFlex for Colonoscopy; and AlveoFlex for Bronchoscopy and Alveoscopy. The company is also involved in the development of pre-clinical research systems, including ProFlex microprobes; Laser Scanning Unit, a high-resolution fibered confocal microscope; and ImageCell software that quantifies data in real time for various applications, such as deep brain imaging, Angiogenesis, peripheral nervous system, GI cancer research, stem cells, and pancreatic cancer imaging. It primarily serves the gastroenterologists and pulmonologists. The company was founded in 2000 and is based in Paris, France.

118 Employees
Last Reported Date: 08/28/14
Founded in 2000

mauna kea technologies (MKEA) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: €270.0K
Compensation as of Fiscal Year 2013.

mauna kea technologies (MKEA) Key Developments

Mauna Kea Technologies Announces Publication of Confirmation Data on the Value of Endomicroscopy for the Characterization of Pancreatic Cystic Neoplasms

Mauna Kea Technologies SAS announced publication of a pilot monocentric study by Dr. Y. Nakaiet al, University of California Irvine Medical Center, Orange, CA. The study results show that needle-based confocal endomicroscopy (nCLE) procedures safely performed with Cellvizio were successfully able to differentiate mucinous from non-mucinous pancreatic cysts with a high degree of accuracy. Results were published recently in the peer-reviewed journal Gastrointestinal Endoscopy. In an article entitled: "Diagnosis of pancreatic cysts: EUS-guided, through-the-needle confocal laser-induced endomicroscopy and cystoscopy trial: DETECT study, the research team led by Dr. Kenneth J. Chang, at UC Irvine report that the use of Cellvizio demonstrated 100% positive predictive value and 100% specificity in characterizing mucinous cysts thanks to the visualization of papillary projections, also called papillae. Researchers were able to confirm the classification of these cysts as mucinous (IPMN) by either surgery or standard tests (e.g, EUS, CEA, cytology, amylase) in a high-certainty diagnosed sub-population. Authors showed nCLE-accuracy data at a level of 89% using this criteria in pancreatic cysts.

Mauna Kea Technologies Announces Positive Results from Focus Pivotal Clinical Trial on Use of Confocal Laser Endomicroscopy in Biliary Cancer Detection

Mauna Kea Technologies announced publication of the final results of the multi-center international prospective FOCUS clinical trial assessing the use of probe-based confocal laser endomicroscopy (pCLE) in the diagnosis of biliary cancer during endoscopic retrograde cholangio-pancreatography (ERCP). In the FOCUS study a total of 112 patients with indeterminate biliary strictures were treated in six centers around the world. Results were published in the peer-reviewed journal Gastrointestinal Endoscopy, the official journal of the American Society of Gastrointestinal Endoscopy (ASGE). The FOCUS trial evaluated the diagnostic performance of pCLE with Cellvizio for the characterization of biliary strictures and thus for the presence of biliary cancer (cholangiocarcinoma). Results show a very significant improvement in the sensitivity of detection of cholangiocarcinoma, from 56% for biopsies to 89% for pCLE. Among the 112 patients enrolled in this study, pCLE correctly diagnosed 88% of patients (Accuracy: 88%, Sensitivity: 89%, Specificity: 88%, Positive Predictive Value: 93%, Negative Predictive Value: 82%) when combined with ERCP. Importantly, tissue sampling (traditional biopsies) was inconclusive for a majority of patients (70 out of 112) while pCLE was inconclusive for only 16 patients, thus helping physicians to correctly identify the condition of 54 of the patients in this indeterminate group. Within this group, pCLE helped identify cancer earlier than traditional methods in 24 patients and correctly ruled out cancer in 30 patients with benign strictures. The information provided by Cellvizio enabled endoscopists to improve patient care by avoiding unnecessary invasive and costly surgical procedures as well as repeat diagnostic procedures. Studies have shown that up to 50 % of patients with indeterminate traditional biopsies undergo invasive bilio-pancreatic surgeries, reducing their long-term survival rates and creating significant unnecessary costs for the healthcare systems.

Mauna Kea Technologies SAS Announces Consolidated Sales Results for the Fourth Quarter and Full Year Ended December 31, 2014

Mauna Kea Technologies SAS announced consolidated sales results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company announced sales of EUR 3,218,000 compared to EUR 2,927,000 for the same period a year ago. For the full year, the company announced sales of EUR 11,016,000 compared to EUR 9,977,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKEA:FP €5.02 EUR -0.10

MKEA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.55 USD 0.00
MELA Sciences Inc $2.81 USD -0.0499
Optiscan Imaging Ltd A$0.07 AUD -0.001
Verisante Technology Inc C$0.11 CAD 0.00
View Industry Companies
 

Industry Analysis

MKEA

Industry Average

Valuation MKEA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAUNA KEA TECHNOLOGIES, please visit www.maunakeatech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.